Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ziconotide - RIEMSER Arzeneimittel/TerSera Therapeutics

Drug Profile

Ziconotide - RIEMSER Arzeneimittel/TerSera Therapeutics

Alternative Names: CI 1009; MVIIA; Prialt; SNX 111; SNX 194; Ziconotide acetate - Jazz Pharmaceuticals/RIEMSER Arzeneimittel

Latest Information Update: 15 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elan Pharmaceuticals
  • Developer Eisai Co Ltd; Elan Pharmaceuticals; Jazz Pharmaceuticals plc; RIEMSER Arzneimittel
  • Class Conotoxins; Neuroprotectants; Non-opioid analgesics; Peptides
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pain
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pain
  • Discontinued Craniocerebral trauma; Stroke

Most Recent Events

  • 06 Nov 2018 Jazz Pharmaceuticals completes the sale of its rights related to ziconotide intrathecal infusion (Prialt) to TerSera Therapeutics in September 2018
  • 02 Jul 2018 Jazz Pharamceuticals enters into a definetive agreement to sell rights related to ziconotide intrathecal infusion to TerSera Therapeutics
  • 23 Apr 2018 RIEMSER Arzneimittel acquires Ziconotide from Eisai Co Ltd in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top